คำอธิบาย
Combining tirzepatide (dual GIP/GLP-1 agonist) with sitagliptin (DPP-4 inhibitor) produces overlapping incretin-based mechanisms with additive hypoglycaemia risk and no meaningful additional benefit over either agent alone.
กลไก
DPP-4 inhibitors prevent degradation of endogenous GLP-1 and GIP; tirzepatide directly activates GLP-1R and GIPR with high affinity, overwhelming the DPP-4 pathway. The combination generates redundant incretin receptor activation with additive glucose-lowering and GI adverse effects.
ความสำคัญทางคลินิก
Pharmacodynamic redundancy offers no proven efficacy benefit; increased risk of nausea, vomiting, and hypoglycaemia (especially if insulin or sulfonylurea is also present) without additional HbA1c reduction.
การจัดการ
Discontinue sitagliptin when initiating tirzepatide; the combination is generally not recommended per treatment guidelines; if both are used, monitor closely for GI side effects and hypoglycaemia.
ข้อจำกัดความรับผิดชอบทางการแพทย์
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.